Skip to main content
Caplight Logo









Cirrus Therapeutics

Cirrus Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://cirrustx.com/

Last Round

Seed

Oct 2, 2025

Total Funding Raised

$11M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cirrus Therapeutics is a biotechnology company developing gene and cell therapies for ocular immunology to treat conditions like age-related macular degeneration (AMD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

ocular immunologyAAV gene therapydry age-related macular degenerationAMDgene therapygeographic atrophyGAIRAK-Mcell therapyRPE cell therapyadeno-associated virusophthalmologypreclinical biotechblinding diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cirrus Therapeutics Comparables

Compare Cirrus Therapeutics with similar companies based on industry and business-model similarity.

Cirrus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Complement Therapeutics GmbH
84%
Luxa Biotechnology
81%
Perceive Bio
81%

Cirrus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 2, 2025

Key People

Founding team and executive leadership

Ying Kai Chan

Co-Founder And CEO

Founding Team

Edward F. Finn

Consulting CFO

Executive Team

Cirrus Therapeutics Investors

Notable investors and investment history

Cirrus Therapeutics investors
InvestorRounds
SEEDS CapitalSeed
ClavystBioSeed
Polaris PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 562% MoM.

  • Jun 27, 2026

    Grew 33% QoQ, from 9 to 12 employees.

Cirrus Therapeutics Filings

Explore SEC and related filing metadata, where available.

Cirrus Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cirrus Therapeutics's valuation, stock price, and market status.

Is Cirrus Therapeutics a public or private company?

Cirrus Therapeutics is a private company.

What is the current stock price of Cirrus Therapeutics?

Cirrus Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Cirrus Therapeutics worth (valuation)?

Valuation information for Cirrus Therapeutics is not publicly available.

Can I buy Cirrus Therapeutics stock?

Cirrus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cirrus Therapeutics's last funding round?

Cirrus Therapeutics's most recent funding round was Seed on October 2, 2025.

Who are the main investors in Cirrus Therapeutics?

Key investors in Cirrus Therapeutics include ClavystBio.

Will Cirrus Therapeutics IPO soon?

No public IPO plans have been announced for Cirrus Therapeutics.

How can I track Cirrus Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cirrus Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range10
Year Founded2022
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?